CC-4047 in Treating Patients With Myelofibrosis : A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 in Patients With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis®
RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. CC-4047 may also stop the growth of cancer cells by blocking blood flow to the cancer. PURPOSE: This trial is studying the side effects and best dose of CC-4047 and to see how well it works in treating patients with myelofibrosis..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
ClinicalTrials.gov - (2019) vom: 30. Dez. Zur Gesamtaufnahme - year:2019 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: April 30, 2008, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 |
|---|
| Study ID: |
NCT00669578 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG000547557 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG000547557 | ||
| 003 | DE-627 | ||
| 005 | 20230425190819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG000547557 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT00669578 | ||
| 035 | |a (UBBS_Klinische_Studien)MC078B | ||
| 035 | |a (UBBS_Klinische_Studien)P30CA015083 | ||
| 035 | |a (UBBS_Klinische_Studien)NCI-2009-01331 | ||
| 035 | |a (UBBS_Klinische_Studien)07-005317 | ||
| 035 | |a (UBBS_Klinische_Studien)PO-MMM-PI-0007 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a CC-4047 in Treating Patients With Myelofibrosis |b A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 in Patients With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis® |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: April 30, 2008, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 | ||
| 520 | |a RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. CC-4047 may also stop the growth of cancer cells by blocking blood flow to the cancer. PURPOSE: This trial is studying the side effects and best dose of CC-4047 and to see how well it works in treating patients with myelofibrosis. | ||
| 650 | 2 | |a Polycythemia Vera | |
| 650 | 2 | |a Primary Myelofibrosis | |
| 650 | 2 | |a Myeloproliferative Disorders | |
| 650 | 4 | |a Medical Condition: Chronic Myeloproliferative Disorders, Secondary Myelofibrosis | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a Phase: Phase 1/Phase 2 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2019) vom: 30. Dez. |
| 773 | 1 | 8 | |g year:2019 |g day:30 |g month:12 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT00669578 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2019 |b 30 |c 12 | ||